AI-Generated Filing Summaries

Micron Technology, Inc. commenced cash tender offers to purchase any and all of its outstanding 5.300% Senior Notes due 2031, 5.650% Senior Notes due 2032, 5.875% Senior Notes due 2033 (two series), 5.800% Senior Notes due 2035, and 6.050% Senior Notes due 2035. The offers expire at 5:00 p.m. New York City time on March 31, 2026, with settlement expected on April 3, 2026.

On March 20, 2026, the Board of QT Imaging Holdings, Inc. approved a base salary increase for CEO Dr. Raluca Dinu to $605,000 per year from $550,000, a $231,993 cash bonus for Dr. Dinu, a $40,576 cash bonus for CFO Jay Jennings, and RSU grants of 519,500 to Dr. Dinu and 2,800 to Mr. Jennings under the 2024 Equity Incentive Plan.

CDT Equity Inc. filed a certificate of amendment to its Second Amended and Restated Certificate of Incorporation on March 24, 2026, to effect a 1-for-25 reverse stock split of its common stock, effective March 26, 2026, at 5:00 p.m. Eastern Time. Trading on a split-adjusted basis under ticker CDT is expected to begin on Nasdaq on March 27, 2026, reducing outstanding shares to approximately 4,722,450.

CDT Equity Inc. filed a certificate of amendment to its Second Amended and Restated Certificate of Incorporation on March 24, 2026, to effect a 1-for-25 reverse stock split of its common stock, effective March 26, 2026, at 5:00 p.m. Eastern Time. Trading on a split-adjusted basis under ticker CDT is expected to begin on Nasdaq on March 27, 2026, reducing outstanding shares to approximately 4,722,450.

Rentokil Initial plc announced the filing of its Annual Report and Financial Statements for the year ended 31 December 2025 with the Financial Conduct Authority and as Form 20-F with the SEC, available on the company's website and SEC site. The company also filed and published the Notice of 2026 Annual General Meeting to be held on 7 May 2026 at Compass House, Crawley.

Rentokil Initial plc announced the filing of its Annual Report and Financial Statements for the year ended 31 December 2025 with the Financial Conduct Authority and as Form 20-F with the SEC, available on the company's website and SEC site. The company also filed and published the Notice of 2026 Annual General Meeting to be held on 7 May 2026 at Compass House, Crawley.

LakeShore Biopharma's Special Committee received a revised preliminary non-binding proposal dated March 24, 2026, from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire all outstanding ordinary shares not owned by them or affiliates at US$0.06 per share, citing arbitral awards of RMB576.5 million as causing a Company Material Adverse Effect.

On March 25, 2026, Ondas Inc. released a slide presentation including supplemental information relating to its financial and operating results for the fourth quarter and full year ended December 31, 2025, furnished as Exhibit 99.1 to this Form 8-K. This provides investors access to the Company's performance details for the period.

BeyondSpring Inc. announced financial results for the full year ended December 31, 2025, reporting net loss from continuing operations of $8.7 million and cash, cash equivalents, and short-term investments of $12.6 million. The company highlighted Phase 3 survival benefits for Plinabulin in EGFR wild-type NSCLC from the DUBLIN-3 study and plans for the confirmatory DUBLIN-4 trial.

Cintas Corporation reported fiscal 2026 third quarter results with revenue of $2.84 billion, up 8.9% from the prior year quarter, gross margin of 51.0%, and diluted EPS of $1.24, up 9.7%. The company raised full-year fiscal 2026 revenue guidance to $11.21 billion to $11.24 billion and adjusted diluted EPS to $4.86 to $4.90, and announced an agreement entered on March 10, 2026, to acquire UniFirst Corporation.

MINISO Group Holding Limited submitted multiple Next Day Disclosure Returns (Exhibits 99.1-99.8) reporting repurchases of ordinary shares on March 18, 19, 20, 23, and 24, 2026, on The Stock Exchange of Hong Kong Limited (stock code 09896) and New York Stock Exchange. Repurchases under mandate dated 12 June 2025 authorizing 124,122,899 shares, with cumulative 11,656,508 shares repurchased as of 24 March 2026 for cancellation.

Innovation Beverage Group Ltd acquired a 51% controlling interest in BlockFuel Energy Inc. by exchanging 127,628 BFE shares for warrants to purchase 3,815,766 IBG ordinary shares at $0.0001 each and provided a $2.5M interest-free unsecured loan to BFE for share repurchase. The company also entered an amended merger agreement making BFE a wholly-owned subsidiary, with BFE holders to own ~90% of the combined energy-focused entity post-closing.

Paychex, Inc. reported third quarter fiscal 2026 results for the three months ended February 28, 2026, with total revenue of $1,808.9 million up 20% and operating income of $792.0 million up 14% year-over-year, driven by the Paycor acquisition and organic growth. Adjusted diluted EPS rose 15% to $1.71, with over $1.5 billion returned to shareholders fiscal year-to-date.

Enlivex Ltd. reported full-year 2025 net income of $1.23 billion and diluted EPS of $25.48, driven by appreciation in treasury and treasury-related derivative assets totaling $2.31 billion as of December 31, 2025. This reflects the company's dual strategy in quality longevity therapeutics and prediction markets treasury, enhancing shareholder value through unrealized gains.

Enlivex Therapeutics Ltd. (ENLV) reported extraordinary FY 2025 results driven by unrealized gains on digital assets, posting net income of $1.24B versus a $15.0M net loss in FY 2024. Operating loss narrowed slightly to $15.0M from $15.9M, reflecting stable R&D expenses of $9.2M (down 13% YoY) amid clinical advancements in osteoarthritis therapy Allocetra. Key drivers included $363.2M income on digital assets (primarily RAIN tokens) and $1.27B gain from fair value change in RAIN purchase option, offset by $382.6M taxes. Balance sheet strengthened with total assets at $2.33B (up from $27.7M), including $606.8M digital assets and $1.71B option value; equity rose to $1.93B. Cash used in operations was $10.4M, with $10.4M financing inflows from share issuances. EPS surged to $27 basic ($25 diluted) from -$0.73. No revenues generated; focus remains on clinical trials. Management states existing resources suffice through 2027, but additional funding needed for commercialization. Digital treasury strategy introduces volatility risks.

UiPath, Inc. appointed Raghavendra Malpani, its current Chief Technology Officer since May 2024, as Chief Product and Technology Officer effective March 25, 2026. Mr. Malpani will receive a base salary of $510,000 and be eligible for an annual performance-based cash bonus targeting 75% of his base salary.

Enzon Pharmaceuticals, Inc. issued a press release on March 25, 2026, announcing the completion of the exchange offer relating to its Series C Non-Convertible Redeemable Preferred Stock. The press release is attached as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure and is not deemed filed under the Exchange Act.

Beyond Meat, Inc. announced on March 25, 2026, that it is delaying the reporting of its fourth quarter and full year 2025 financial results until March 31, 2026 after market close due to a material weakness in internal control over financial reporting related to inventory provisioning and errors identified in prior 2025 quarterly financial statements. Management believes the errors are immaterial and plans prospective corrections.

Bitmine Immersion Technologies, Inc. announced the launch of MAVAN, its proprietary institutional-grade Ethereum staking platform, designed for institutions with U.S.-based infrastructure. At launch, MAVAN manages 3,142,643 staked ETH valued at $6.8 billion, positioning Bitmine as the largest Ethereum staking service provider globally.

IceCure Medical announced positive 5-year top-line results from the ICESECRET clinical trial of ProSense® cryoablation for small renal masses in kidney cancer patients, with 83.9% recurrence-free rate at median four-year follow-up overall and 89.4% in the subgroup with tumors ≤3 cm and no prior kidney cancer. The data supports broader commercial adoption of ProSense® in approved markets including the U.S. and Europe.

Stone Point Credit Income Fund issued and sold 933,048.462 common shares, par value $0.001 per share, at a net asset value of $24.8299 for an aggregate offering price of $23,167,500.00 on March 1, 2026, pursuant to subscription agreements with accredited investors, exempt from Securities Act registration under Section 4(a)(2), Rule 506 of Regulation D, and Regulation S.

CMC declared a regular quarterly cash dividend of $0.20 per share on its common stock, an increase of $0.02 or 11% from the dividend paid in February 2026. The dividend, marking the 246th consecutive quarterly payment, is payable on April 15, 2026, to stockholders of record as of April 6, 2026.

POSCO Holdings Inc. qualified as a high-dividend company under Article 104-27 of the Act on Restriction of Special Taxation, as dividend income in the immediate preceding business year (2024) did not decrease against the base year (2024). Dividend per share remains KRW 10,000 for 2024 and 2025, though total 2025 dividend is lower due to 255,428 fewer outstanding shares after August 2024 treasury share cancellation.

Brookfield and La Caisse entered into a definitive arrangement agreement to acquire all issued and outstanding Class A common shares of Boralex Inc. for $37.25 in cash per share, representing a 31.8% premium over the March 20, 2026 TSX closing price and implying a $9.0 billion enterprise value. The transaction, unanimously approved by Boralex's board, is expected to close by Q4 2026 subject to shareholder and regulatory approvals.

Zhihu Inc. announced unaudited fourth quarter and fiscal year 2025 financial results, with Q4 total revenues of RMB643.5 million and FY total revenues of RMB2,749.0 million. The company achieved its first full-year non-GAAP profitability with adjusted net income of RMB37.9 million, amid a Q4 goodwill impairment of RMB126.3 million.

Tower Semiconductor Ltd. and Nuvoton Technology Corporation Japan, along with TPSCo, entered a framework agreement for strategic restructuring of TPSCo's operations, where Tower gains full ownership of the 12-inch Uozu fab and foundry business, while the 8-inch Tonami fab remains in TPSCo becoming wholly owned by NTCJ for a $25 million payment to Tower. This enhances operational focus and global competitiveness, with closing expected April 1, 2027 subject to approvals.

Real Messenger Corporation announced entry into a non-binding memorandum of understanding with a publicly traded U.S. real estate brokerage company to explore deploying its integrated real estate technology platform, including CRM, messaging, listing management, lead generation, transaction management, and analytics, within the brokerage's agent network. A definitive agreement is required for any deployment under a commercial licensing framework, with no assurance it will be reached.

PTC Therapeutics, Inc. appointed Jessica Chutter to its board of directors effective March 24, 2026, filling a vacancy as a Class I director with term expiring at the 2026 annual stockholder meeting. Ms. Chutter, with over 40 years at Morgan Stanley including as Chair of Biotechnology Investment Banking, will receive compensation per the outside director policy including a $50,000 annual retainer and specified equity grants.

CarParts.com, Inc. entered a Purchase Agreement on March 21, 2026, to issue and sell 10,000,000 shares of common stock at $0.80 per share for $8.0 million gross proceeds in a private placement, with net proceeds to fund inventory investments. Accompanying Investor Rights Agreement and Convertible Note Amendments were executed, alongside a press release on JC Whitney collaboration with A-Premium.

Nasus Pharma Ltd. (NSRX), a clinical-stage biotech developing intranasal drugs for emergencies, reported a net loss of $5.9M for FY 2025 ending December 31, 2025, up 282% YoY from $1.5M in 2024 and $1.1M in 2023. Operating expenses rose to $4.9M from $1.1M YoY, driven by $2.2M R&D (up 568%) and $2.7M G&A (up 259%), reflecting Phase 2 trials for NS002 intranasal Epinephrine and IPO costs. No revenue generated, as expected for pre-commercial stage. Balance sheet strengthened post-IPO: total assets $5.0M (cash $1.2M, short-term deposit $3.0M), equity $2.8M vs. $3.2M deficit prior. Cash burn from ops $4.9M offset by $8.9M financing (IPO net $8.5M), yielding $980K net cash increase. EPS -$1 basic/diluted (8.0M weighted shares). Liquidity supports ops to Q2 2027 post-$15M Feb 2026 raise. Focus on NS002 Phase 3 (Q4 2026), NS001 partnering; substantial doubt on going concern noted due to losses.